Medwell Capital obtained an exclusive worldwide license to proprietary technology developed at the MS Patient Care and Research Clinic at the University of Alberta for the treatment of MS. The compound, dirucotide (MBP8298), is a synthetic myelin basic protein peptide composed of 17 amino acids which is intravenously injected (every six months) into MS patients as a therapeutic treatment.
capital | Australian Capital Territory | venture capital | Capital (political) | capital city | Bain Capital | Capital One | Capital Centre | European Capital of Culture | Capital punishment | Capital city | TPG Capital | Duntroon, Australian Capital Territory | Kingston, Australian Capital Territory | Financial capital | Cerberus Capital Management | Capital FM | Capital | Venture capital | Capital Region International Airport | capital punishment | Sequoia Capital | Oaktree Capital Management | Ngunnawal, Australian Capital Territory | GE Capital | Casey, Australian Capital Territory | Capital punishment in the United States | Capital One Bowl | Belconnen, Australian Capital Territory | Beijing Capital International Airport |